Psoriasis treatment patterns: a retrospective claims study.
Objective: The objective was to characterize psoriasis treatment patterns, including estimating persistence and describing subsequent events (i.e. switching and restarting) for all systemic therapies. Methods: This retrospective cohort study utilized Truven MarketScan databases from 1 January 2014 to 31 December 2016 to investigate persistence, switching and restarting in new users of systemic psoriasis medications. Descriptive statistics, time-to-event analyses and a Cox proportional hazards regression were conducted. Results: A total of 5205 patients met inclusion criteria. Regardless of treatment type, >50% lost persistence by 12 months. Patients newly initiating acitretin or non-TNF biologic experienced the highest loss of persistence (85.2%, 73.8%, respectively). Patients initiating a TNF-α inhibitor or apremilast experienced the lowest loss (51.8%, 56.4% respectively). Treatment type had a statistically significant effect on persistence loss (adjusted hazard ratio: 0.86, 95% CI: 0.81, 0.91). Restarting was the most commonly observed event for patients on an oral or biologic (60.2%, 79.9%, respectively). The most common switch from an oral was to a TNF-α inhibitor, while apremilast often followed biologics. Conclusion: Most patients lost persistence on initial treatment by 12 months, and the majority restarted treatment. This may indicate poor compliance or the cyclical nature of psoriasis. More patients switched from an oral to biologic than vice versa, likely due to formulary design and preference for orals. Studies are needed to investigate underlying reasons and patient characteristics that differentiate treatment utilization.
['Higa|Sara|S|', 'Devine|Beth|B|', 'Patel|Vaishali|V|', 'Baradaran|Sarah|S|', 'Wang|Degang|D|', 'Bansal|Aasthaa|A|']
D000328:Adult D000368:Aged D001688:Biological Products D005260:Female D006801:Humans D008297:Male D008875:Middle Aged D016016:Proportional Hazards Models D011565:Psoriasis D012189:Retrospective Studies D013792:Thalidomide D014409:Tumor Necrosis Factor-alpha
psoriasis treatment patterns Observational research claims data